Glaukos (GKOS) Q1 2026: iDoseTR Drives 58% U.S. Glaucoma Surge, Epioxa Launch Expands Access
Glaukos posted record Q1 results, propelled by iDoseTR’s rapid adoption in U.S. glaucoma and the early rollout of Epioxa in corneal health, prompting a full-year guidance increase. Strategic investments in commercial infrastructure and payer access are accelerating market expansion, while disciplined capital allocation underpins a pathway to profitability. The company’s focus on transforming care standards in ophthalmology is reshaping the competitive landscape and setting up for sustained growth into the next decade.
Summary
- iDoseTR Adoption Accelerates: U.S. glaucoma franchise momentum is broadening as iDoseTR penetration expands across payer segments and regions.
- Epioxa Launch Gains Traction: Early site-of-care and payer access for keratoconus therapy signals growing demand and market expansion potential.
- Profitability Pathway Strengthens: Operating leverage and disciplined investments support a clear trajectory toward sustainable cash flow breakeven.
Performance Analysis
Glaukos delivered record consolidated net sales for Q1, up 41% YoY, with standout performance in its U.S. glaucoma segment. The iDoseTR, sustained-release glaucoma implant, generated approximately $54 million in sales, fueling 58% growth in U.S. glaucoma and broadening adoption among both established and new Medicare Administrative Contractor (MAC) regions. International glaucoma also posted double-digit gains, though management flagged that currency tailwinds are expected to fade and competitive trialing will intensify in key markets.
Corneal health net sales climbed 15% YoY, driven by early contributions from Epioxa, a novel, incision-free cross-linking therapy for keratoconus. The launch strategy prioritized building a broad site-of-care network and payer coverage, with 65% of the U.S. population already reached and a path to 95% coverage underway. Management highlighted measured adoption in the initial phase as reimbursement pathways mature, with a permanent J-code set to streamline access from July 2026.
- U.S. Glaucoma Outperformance: iDoseTR’s clinical and commercial traction is accelerating the shift toward interventional glaucoma care.
- International Growth Moderates: Currency and competitive dynamics will temper further upside in global glaucoma as the year progresses.
- Corneal Health Transition: Epioxa’s launch is driving a strategic shift from legacy products, though payer adoption remains a gating factor for near-term ramp.
Operating leverage improved as top-line growth outpaced expense increases, and management reiterated its focus on ROI-driven investments to support both growth and margin expansion.
Executive Commentary
"Our first quarter results reflect strong execution across our global commercial and development priorities, highlighting the commitment of our teams, strength of our differentiating technology platforms, and our continued progression as an increasingly diversified leader in ophthalmology."
Tom Burns, Chairman and CEO
"We continue to reinvest in the business and reinvest in these commercial launches. Our operating expenses will grow this year, year over year, but still in the high teens and still showing that operating leverage overall as we progress throughout the year."
Alex Thurman, Chief Financial Officer
Strategic Positioning
1. Transforming Glaucoma Treatment with iDoseTR
iDoseTR is redefining the standard of care in glaucoma, driving both physician adoption and payer acceptance. The company is expanding its base of trained surgeons and active accounts, while investing in education and real-world evidence to accelerate the shift toward interventional care. Broad-based growth across MACs and commercial payers signals durable market expansion, with re-administration approvals and ongoing Phase IV studies further strengthening the clinical and reimbursement foundation.
2. Epioxa Launch: Building a New Market in Keratoconus
Epioxa’s launch strategy focuses on market development, with investments in patient awareness, provider training, and payer engagement. The rapid build-out of a site-of-care network and early payer policy wins (including coverage for over 100 million commercial lives) are crucial steps in overcoming historical underdiagnosis and undertreatment. The upcoming permanent J-code is expected to accelerate adoption and streamline reimbursement, while DTC (direct-to-consumer) initiatives and specialty pharmacy partnerships will support broader access.
3. Pipeline and Platform Diversification
Glaukos is advancing a robust pipeline across five therapeutic platforms, including pivotal trials for iDoseT-Rex, iStent Infinite, and novel corneal health technologies. The pipeline is designed to both reinforce leadership in core markets and unlock new indications, with management highlighting the potential for future market expansion as customized algorithms and next-generation products come online.
4. Commercial Execution and Capital Discipline
Disciplined capital allocation remains central, with investments prioritized for ROI and near-term operating leverage. Management is scaling commercial teams and infrastructure in step with reimbursement progress, ensuring that spend on awareness and DTC is phased to maximize return and minimize risk. Operating expense growth will remain moderate, supporting a clear path to profitability as new products ramp.
Key Considerations
Glaukos’ quarter was defined by decisive commercial execution, strategic investment in market development, and disciplined financial management. The company is balancing aggressive growth initiatives with a focus on operating leverage and cash flow breakeven, while navigating evolving payer and competitive landscapes.
Key Considerations:
- Reimbursement Expansion: iDoseTR now has access pathways for 99% of commercial and Medicare Advantage patients, with policy coverage for about half.
- Market Development for Epioxa: Early site-of-care and payer adoption are strong, but durable growth depends on payer policy expansion and streamlined reimbursement.
- Operating Leverage: Expense growth is being managed in line with revenue, supporting a path to sustainable profitability as product mix shifts to higher-margin therapies.
- Pipeline Execution: Timely progress on pivotal trials and next-generation platforms will be critical for sustaining long-term growth and defending competitive position.
Risks
Key risks include potential reimbursement headwinds, particularly if LCDs (Local Coverage Determinations) are introduced or if payer policy momentum stalls. Competitive trialing in international glaucoma markets could pressure growth rates, while the pace of Epioxa adoption remains contingent on further payer and provider alignment. Operating expense discipline will be tested as commercial investments ramp, and any delays in pipeline execution could impact the long-term growth profile.
Forward Outlook
For Q2 2026, Glaukos guided to:
- Flat sequential iDoseTR expansion in U.S. glaucoma
- High single-digit growth in international glaucoma as currency tailwinds fade
- Corneal health dip YoY in Q2 as the Botrexa-to-Epioxa transition continues
For full-year 2026, management raised net sales guidance to $620–$635 million, reflecting:
- Low 30% growth in U.S. glaucoma
- Low double-digit growth in international glaucoma
- High single-digit growth in corneal health, with acceleration expected post-J-code implementation
Management highlighted continued investment in commercial expansion, payer engagement, and pipeline development as key drivers for the year.
- Permanent J-code for Epioxa expected to unlock faster adoption in H2
- Operating leverage and cash flow breakeven remain near-term priorities
Takeaways
Glaukos is capitalizing on strong U.S. glaucoma momentum and early Epioxa traction to accelerate its transformation into a diversified ophthalmic leader.
- iDoseTR Scaling Rapidly: Broad-based adoption and payer access are solidifying Glaukos’ leadership in interventional glaucoma, with re-administration and combination use expanding the addressable market.
- Epioxa Market Creation Underway: Early network and payer wins set the stage for a multi-year ramp, but execution on awareness, access, and reimbursement will determine the ultimate market size.
- Watch for Pipeline Milestones: Progress on pivotal trials and next-generation launches will be critical for sustaining momentum and expanding the company’s total addressable market.
Conclusion
Glaukos enters Q2 with record momentum, a strengthened outlook, and a disciplined approach to scaling its commercial and clinical platforms. The company’s dual focus on execution and capital efficiency positions it to extend its leadership in ophthalmic innovation while building a foundation for durable, profitable growth.
Industry Read-Through
Glaukos’ results highlight a broader industry shift toward interventional ophthalmology, where device-pharma hybrids and procedural therapies are gaining traction with both providers and payers. The company’s success in aligning reimbursement, clinical evidence, and commercial execution provides a playbook for others seeking to redefine care paradigms in underpenetrated markets. Early investments in payer engagement and network build-out are proving essential for new therapy launches, while the measured approach to DTC and discretionary spend signals a maturing discipline in medtech commercialization. Competitors in ophthalmology and other specialty therapeutics should note the importance of robust real-world evidence and phased market development to drive adoption and unlock new growth vectors.